Adamas Pharmaceuticals’ (ADMS) “Outperform” Rating Reiterated at JMP Securities
JMP Securities reissued their outperform rating on shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) in a research note released on Friday, Marketbeat Ratings reports. JMP Securities currently has a $33.00 price target on the specialty pharmaceutical company’s stock, up from their previous price target of $29.00.
Several other research firms have also recently weighed in on ADMS. BidaskClub cut Adamas Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, July 19th. Mizuho reissued a buy rating and issued a $26.00 price target on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 6th. Zacks Investment Research cut Adamas Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, May 3rd. Cowen and Company set a $45.00 target price on Adamas Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, August 9th. Finally, Noble Financial restated a buy rating on shares of Adamas Pharmaceuticals in a report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. Adamas Pharmaceuticals presently has an average rating of Hold and a consensus target price of $32.50.
Shares of Adamas Pharmaceuticals (ADMS) opened at 20.27 on Friday. Adamas Pharmaceuticals has a 52-week low of $12.10 and a 52-week high of $21.44. The firm’s market cap is $456.36 million. The company’s 50-day moving average is $16.54 and its 200 day moving average is $16.78.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.81) by $0.12. Adamas Pharmaceuticals had a negative return on equity of 52.91% and a negative net margin of 10,499.65%. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.03 million. During the same quarter last year, the firm posted ($0.78) earnings per share. Adamas Pharmaceuticals’s revenue was down 90.9% compared to the same quarter last year. On average, analysts expect that Adamas Pharmaceuticals will post ($3.79) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Adamas Pharmaceuticals’ (ADMS) “Outperform” Rating Reiterated at JMP Securities” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/29/adamas-pharmaceuticals-adms-outperform-rating-reiterated-at-jmp-securities.html.
In other news, major shareholder Great Point Partners Llc sold 350,000 shares of the company’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $17.05, for a total transaction of $5,967,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders have sold 731,041 shares of company stock valued at $12,476,149. Corporate insiders own 29.00% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC acquired a new position in shares of Adamas Pharmaceuticals during the second quarter worth approximately $109,000. American International Group Inc. raised its position in shares of Adamas Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock worth $180,000 after buying an additional 682 shares during the period. Virtu KCG Holdings LLC acquired a new position in shares of Adamas Pharmaceuticals during the second quarter worth approximately $184,000. Wells Fargo & Company MN raised its position in shares of Adamas Pharmaceuticals by 28.4% in the first quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock worth $266,000 after buying an additional 3,358 shares during the period. Finally, Trexquant Investment LP acquired a new position in shares of Adamas Pharmaceuticals during the first quarter worth approximately $287,000. Institutional investors own 69.24% of the company’s stock.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Stock Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.